(Alliance News) - Hikma Pharmaceuticals PLC on Thursday said the US Court of Appeals for the Federal Circuit upheld a ruling by the US District Court for the District of Nevada which found that Hikma's generic version of Vascepa does not infringe any valid claim of six key Amarin-owned patents.
The London-headquartered pharmaceutical company said it has received the US Food & Drug Administration approval for the product in May 2020 and is working towards a launch.
Vascepa is a prescription medicine that is indicated, in part, as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
"We are very pleased with the Federal Circuit's swift decision and to be one step closer to launching a generic version of this important medicine for US patients and healthcare providers, helping us to continue putting better health, within reach, every day," said Brian Hoffmann, president of Hikma Generics.
"Today's decision demonstrates Hikma's ability to successfully challenge patents on important medicines and to provide value to our customers and millions of patients across the US," added Hoffmann.
Hikma shares closed 0.3% lower in London on Thursday at 2,412.00 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Hikma Pharmaceuticals (HIK)